公开(公告)号：WO2008094849A2

公开(公告)日：2008-08-07

申请号：PCT/US2008/052165

申请日：2008-01-28

Applicant: UNITED THERAPEUTICS CORPORATION ,  DWEK, Raymond, Allen ,  SCANLAN, Christopher ,  DUNLOP, David, Cameron ,  MANSAB, Fatma, Mii ,  TULLY, Sarah, Erin ,  WENTWORTH, Paul ,  ZITZMANN, Nicole

Inventor： DWEK, Raymond, Allen ,  SCANLAN, Christopher ,  DUNLOP, David, Cameron ,  MANSAB, Fatma, Mii ,  TULLY, Sarah, Erin ,  WENTWORTH, Paul ,  ZITZMANN, Nicole

CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K39/385 ,  A61K2039/6087 ,  A61K2039/645 ,  C07K14/005 ,  C12N2740/16122 ,  C12N2740/16134

Abstract: Disclosed are compositions and methods useful for inducing an immunogenic response in a subject or host. In particular, the compositions and methods may be directed to carbohydrate HIV vaccines and to methods of producing a carbohydrate HIV vaccine by introducing antigenic sugars into mimics of the glycans of the HIV envelope glycoproteins gpl20 and gp41.

Abstract translation: 公开了可用于在受试者或宿主中诱导免疫原性应答的组合物和方法。 特别地，组合物和方法可以涉及碳水化合物HIV疫苗，并且涉及通过将抗原性糖引入HIV包膜糖蛋白gp120和gp41的聚糖的模拟物中来产生碳水化合物HIV疫苗的方法。

公开(公告)号：WO2008088581A2

公开(公告)日：2008-07-24

申请号：PCT/US2007/075080

申请日：2007-08-02

Applicant: UNITED THERAPEUTICS CORPORATION ,  DWEK, Raymond, A. ,  NICHITA-BRANZA, Norica ,  PETRESCU, Stefana ,  POLLOCK, Stephanie ,  RUDD, Pauline ,  SCANLAN, Christopher ,  ZITZMANN, Nicole

Inventor： DWEK, Raymond, A. ,  NICHITA-BRANZA, Norica ,  PETRESCU, Stefana ,  POLLOCK, Stephanie ,  RUDD, Pauline ,  SCANLAN, Christopher ,  ZITZMANN, Nicole

CPC classification number: A61K31/70 ,  A61K9/1271 ,  A61K9/1272 ,  A61K38/212 ,  A61K47/6425 ,  A61K47/6911 ,  A61K2300/00

Abstract: One can treat a viral infection such as hepatitis B (HBV), hepatitis C (HCV), and bovine viral diarrhea virus (BVDV) infections via the delivery of pH sensitive liposomes directly into the endoplasmic reticulum (ER) membrane. Two exemplary liposome formulations are DOPE/CHEMS (DC liposomes) and DOPE/CHEMS/PEG-PE (DCPP liposomes). DC and DCPP liposomes can optimize the intracellular delivery of N -butyl deoxynojirimycin ( N B-DNJ), and consequently increase the in vivo activity of this iminosugar several orders of magnitude, and could be used in combination with other therapeutic agents such as interferon and/or ribavirin. The optimized release of N B-DNJ directly into the ER can be also applied for the treatment of other viruses, for which N B-DNJ is known to be an effective antiviral, such as human immunodeficiency virus (HIV).

Abstract translation: 通过将pH敏感的脂质体直接递送到内质网（ER）膜中，可以治疗乙型肝炎（HBV），丙型肝炎（HCV）和牛病毒性腹泻病毒（BVDV）感染的病毒感染。 两种示例性的脂质体制剂是DOPE / CHEMS（DC脂质体）和DOPE / CHEMS / PEG-PE（DCPP脂质体）。 DC和DCPP脂质体可以优化N-丁基脱氧野尻霉素（NB-DNJ）的细胞内递送，从而增加这种亚氨基二糖的体内活性几个数量级，并且可以与其它治疗剂如干扰素和/ 或利巴韦林。 NB-DNJ直接进入ER的优化释放也可以用于其他病毒的治疗，已知NB-DNJ是有效的抗病毒药物，如人类免疫缺陷病毒（HIV）。

公开(公告)号：WO2013102146A1

公开(公告)日：2013-07-04

申请号：PCT/US2012/072184

申请日：2012-12-28

Applicant: DECA TECHNOLOGIES, INC. ,  SCANLAN, Christopher

Inventor： SCANLAN, Christopher

IPC: H01L21/50 ,  H01L23/48

CPC classification number: H01L21/76838 ,  H01L21/56 ,  H01L21/561 ,  H01L21/563 ,  H01L21/568 ,  H01L21/78 ,  H01L23/28 ,  H01L23/3114 ,  H01L23/3128 ,  H01L23/48 ,  H01L23/562 ,  H01L24/11 ,  H01L24/13 ,  H01L24/19 ,  H01L24/20 ,  H01L24/92 ,  H01L24/94 ,  H01L24/96 ,  H01L24/97 ,  H01L2224/12105 ,  H01L2224/131 ,  H01L2224/2101 ,  H01L2224/214 ,  H01L2224/215 ,  H01L2224/32225 ,  H01L2224/73267 ,  H01L2224/92 ,  H01L2224/94 ,  H01L2224/96 ,  H01L2224/97 ,  H01L2924/181 ,  H01L2924/3511 ,  H01L2224/20 ,  H01L2224/11 ,  H01L2924/01029 ,  H01L2924/014 ,  H01L2924/01028 ,  H01L2924/0105 ,  H01L2224/83 ,  H01L2924/00 ,  H01L2224/19 ,  H01L23/3164 ,  H01L2224/03

Abstract: A method of manufacturing a semiconductor chip comprising placing a plurality of die units each having an active front surface and a back surface facing front surface up on an encapsulant layer, encapsulating the plurality of die units on the active surface of the encapsulant layer with an encapsulant covering a front surface and four side surfaces of each of the plurality of die units, and exposing, through the encapsulation on the front surface, conductive interconnects electrically connecting a die bond pad to redistribution layer.

Abstract translation: 一种制造半导体芯片的方法，包括将具有活性前表面和背面的前表面的多个模具单元放置在密封剂层上，用密封剂将多个模具单元封装在密封剂层的活性表面上 覆盖多个模具单元中的每一个的前表面和四个侧表面，并且通过前表面上的封装暴露导电互连件，以将管芯接合焊盘电连接到再分配层。

公开(公告)号：WO2013102137A2

公开(公告)日：2013-07-04

申请号：PCT/US2012/072164

申请日：2012-12-28

Applicant: DECA TECHNOLOGIES, INC. ,  SCANLAN, Christopher

Inventor： SCANLAN, Christopher

IPC: H01L23/498 ,  H01L21/56 ,  H01L21/60

CPC classification number: H01L21/56 ,  H01L21/561 ,  H01L21/568 ,  H01L21/78 ,  H01L23/31 ,  H01L23/3114 ,  H01L23/3128 ,  H01L23/48 ,  H01L23/562 ,  H01L24/11 ,  H01L24/13 ,  H01L24/19 ,  H01L24/20 ,  H01L24/92 ,  H01L24/94 ,  H01L24/96 ,  H01L2224/12105 ,  H01L2224/131 ,  H01L2224/2101 ,  H01L2224/214 ,  H01L2224/215 ,  H01L2224/92 ,  H01L2224/94 ,  H01L2224/96 ,  H01L2924/181 ,  H01L2924/3511 ,  H01L2224/20 ,  H01L2924/01029 ,  H01L2924/014 ,  H01L2224/11 ,  H01L2924/01028 ,  H01L2924/0105 ,  H01L23/3164 ,  H01L2924/00

Abstract: A method for manufacturing a device package may include constructing a spacer element coupled with a surface of a semiconductor die unit, where the spacer element is configured to create a gap between the semiconductor die unit and a surface of a carrier, and encapsulating the semiconductor die unit within a mold compound, where the encapsulating includes introducing the mold compound into the gap.

Abstract translation: 用于制造器件封装的方法可以包括构造与半导体管芯单元的表面耦合的间隔元件，其中间隔元件构造成在半导体管芯单元和载体的表面之间产生间隙，并且封装半导体管芯 单元在模具化合物中，其中包封包括将模具化合物引入到间隙中。

公开(公告)号：WO2008094849A3

公开(公告)日：2008-12-31

申请号：PCT/US2008052165

申请日：2008-01-28

Applicant: UNITED THERAPEUTICS CORP ,  DWEK RAYMOND ALLEN ,  SCANLAN CHRISTOPHER ,  DUNLOP DAVID CAMERON ,  MANSAB FATMA MII ,  TULLY SARAH ERIN ,  WENTWORTH PAUL ,  ZITZMANN NICOLE

Inventor： DWEK RAYMOND ALLEN ,  SCANLAN CHRISTOPHER ,  DUNLOP DAVID CAMERON ,  MANSAB FATMA MII ,  TULLY SARAH ERIN ,  WENTWORTH PAUL ,  ZITZMANN NICOLE

IPC: A61K39/21

CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K39/385 ,  A61K2039/6087 ,  A61K2039/645 ,  C07K14/005 ,  C12N2740/16122 ,  C12N2740/16134

Abstract: Disclosed are compositions and methods useful for inducing an immunogenic response in a subject or host. In particular, the compositions and methods may be directed to carbohydrate HIV vaccines and to methods of producing a carbohydrate HIV vaccine by introducing antigenic sugars into mimics of the glycans of the HIV envelope glycoproteins gpl20 and gp41.

Abstract translation: 公开了用于在受试者或宿主中诱导免疫原性应答的组合物和方法。 特别地，组合物和方法可以涉及碳水化合物HIV疫苗，以及通过将抗原性糖引入HIV包膜糖蛋白gp120和gp41的聚糖的模拟物来生产碳水化合物HIV疫苗的方法。

公开(公告)号：WO2013110946A1

公开(公告)日：2013-08-01

申请号：PCT/GB2013/050164

申请日：2013-01-25

Applicant: CRISPIN, Matthew David Max ,  SCANLAN, Christopher Neil

Inventor： CRISPIN, Matthew David Max ,  SCANLAN, Christopher Neil

IPC: A61K39/395 ,  C12N9/24 ,  C07K16/32

CPC classification number: A61K39/3955 ,  A61K38/47 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/41 ,  C12Y302/01096 ,  A61K2300/00

Abstract: The invention relates to compositions comprising therapeutic antibodies, and uses and methods for increasing the potency of therapeutic antibodies. In particular, the invention provides a composition comprising (i) an agent which reduces Fc receptor binding of endogenous serum antibodies, and (ii) a therapeutic antibody, preferably a therapeutic antibody which is resistant to the agent. The therapeutic antibody may be administered to the subject after a set time interval, or the blood of the subject may be treated with the agent prior to administration of the therapeutic antibody.

Abstract translation: 本发明涉及包含治疗性抗体的组合物，以及用于增加治疗性抗体效力的用途和方法。 特别地，本发明提供一种组合物，其包含（i）降低内源性血清抗体的Fc受体结合的试剂，和（ii）治疗性抗体，优选对该试剂具有抗性的治疗性抗体。 治疗性抗体可以在设定的时间间隔后施用于受试者，或者可以在施用治疗性抗体之前用试剂治疗受试者的血液。

公开(公告)号：WO2011103216A2

公开(公告)日：2011-08-25

申请号：PCT/US2011025129

申请日：2011-02-16

Applicant: CYPRESS SEMICONDUCTOR CORP ,  SCANLAN CHRISTOPHER ,  OLSON TIM

Inventor： SCANLAN CHRISTOPHER ,  OLSON TIM

IPC: H01L21/60

CPC classification number: H01L22/12 ,  G06F17/5077 ,  H01L21/56 ,  H01L21/568 ,  H01L21/768 ,  H01L22/20 ,  H01L23/3135 ,  H01L23/49816 ,  H01L23/52 ,  H01L23/5226 ,  H01L23/544 ,  H01L24/19 ,  H01L24/20 ,  H01L2223/54426 ,  H01L2223/54473 ,  H01L2223/54486 ,  H01L2224/12105 ,  H01L2224/131 ,  H01L2224/14131 ,  H01L2224/2105 ,  H01L2224/221 ,  H01L2224/8212 ,  H01L2924/12042 ,  H01L2924/14 ,  H01L2924/181 ,  Y02P80/30 ,  H01L2924/014 ,  H01L2924/00

Abstract: An adaptive patterning method and system for fabricating panel based package structures is described. Misalignment for individual device units in a panel or reticulated wafer may be adjusted for by measuring the position of each individual device unit and forming a unit-specific pattern over each of the respective device units.

Abstract translation: 描述了一种用于制造基于面板的封装结构的自适应图案化方法和系统。 可以通过测量每个单独设备单元的位置并在每个相应设备单元上形成单位特定图案来调整面板或网状晶片中的各个设备单元的未对准。

公开(公告)号：WO2008088581A3

公开(公告)日：2009-02-26

申请号：PCT/US2007075080

申请日：2007-08-02

Applicant: UNITED THERAPEUTICS CORP ,  DWEK RAYMOND A ,  NICHITA-BRANZA NORICA ,  PETRESCU STEFANA ,  POLLOCK STEPHANIE ,  RUDD PAULINE ,  SCANLAN CHRISTOPHER ,  ZITZMANN NICOLE

Inventor： DWEK RAYMOND A ,  NICHITA-BRANZA NORICA ,  PETRESCU STEFANA ,  POLLOCK STEPHANIE ,  RUDD PAULINE ,  SCANLAN CHRISTOPHER ,  ZITZMANN NICOLE

IPC: A61K31/70 ,  A61K9/127 ,  A61K38/02 ,  A61K38/08 ,  A61P31/14 ,  A61P31/18 ,  A61P31/20

CPC classification number: A61K31/70 ,  A61K9/1271 ,  A61K9/1272 ,  A61K38/212 ,  A61K47/6425 ,  A61K47/6911 ,  A61K2300/00

Abstract: One can treat a viral infection such as hepatitis B (HBV), hepatitis C (HCV), and bovine viral diarrhea virus (BVDV) infections via the delivery of pH sensitive liposomes directly into the endoplasmic reticulum (ER) membrane. Two exemplary liposome formulations are DOPE/CHEMS (DC liposomes) and DOPE/CHEMS/PEG-PE (DCPP liposomes). DC and DCPP liposomes can optimize the intracellular delivery of N-butyl deoxynojirimycin (NB-DNJ), and consequently increase the in vivo activity of this iminosugar several orders of magnitude, and could be used in combination with other therapeutic agents such as interferon and/or ribavirin. The optimized release of NB-DNJ directly into the ER can be also applied for the treatment of other viruses, for which NB-DNJ is known to be an effective antiviral, such as human immunodeficiency virus (HIV).

Abstract translation: 通过将pH敏感的脂质体直接递送到内质网（ER）膜中，可以治疗乙型肝炎（HBV），丙型肝炎（HCV）和牛病毒性腹泻病毒（BVDV）感染的病毒感染。 两种示例性的脂质体制剂是DOPE / CHEMS（DC脂质体）和DOPE / CHEMS / PEG-PE（DCPP脂质体）。 DC和DCPP脂质体可以优化N-丁基脱氧野尻霉素（NB-DNJ）的细胞内递送，从而增加这种亚氨基二糖的体内活性几个数量级，并且可以与其它治疗剂如干扰素和/ 或利巴韦林。 NB-DNJ直接进入ER的优化释放也可以用于其他病毒的治疗，已知NB-DNJ是有效的抗病毒药物，如人类免疫缺陷病毒（HIV）。

公开(公告)号：WO2008012555A2

公开(公告)日：2008-01-31

申请号：PCT/GB2007/002861

申请日：2007-07-27

Applicant: ISIS INNOVATION LIMITED ,  CRISPIN, Matthew, David, Max ,  SCANLAN, Christopher ,  PLATT, Frances, Mary ,  WILLISON, Hugh, John

Inventor： CRISPIN, Matthew, David, Max ,  SCANLAN, Christopher ,  PLATT, Frances, Mary ,  WILLISON, Hugh, John

CPC classification number: A61K31/195 ,  A61K31/197 ,  A61K31/40 ,  A61K31/42 ,  A61K31/431 ,  A61K31/445 ,  A61K31/513 ,  A61K31/52 ,  A61K31/5375 ,  A61K31/58 ,  A61K31/6615 ,  A61K31/675 ,  A61K31/685 ,  A61K31/7008 ,  A61K31/7012 ,  A61K31/7034 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/708

Abstract: The present invention provides the use of an inhibitor of glycolipid biosynthesis in the manufacture of a medicament for the treatment of a glycolipid-mediated autoimmune disease.

Abstract translation: 本发明提供糖脂生物合成抑制剂在制备用于治疗糖脂介导的自身免疫疾病的药物中的用途。

公开(公告)号：WO2006099592A3

公开(公告)日：2007-12-21

申请号：PCT/US2006009838

申请日：2006-03-16

Applicant: UNIV OXFORD ,  DWEK RAYMOND A ,  RUDD PAULINE M ,  RITCHIE GAYLE ,  SCANLAN CHRISTOPHER ,  CRISPIN M D MAX

Inventor： DWEK RAYMOND A ,  RUDD PAULINE M ,  RITCHIE GAYLE ,  SCANLAN CHRISTOPHER ,  CRISPIN M D MAX

IPC: A61K39/21 ,  C07K14/16 ,  C12N7/00 ,  C12P1/02 ,  C12P21/02

CPC classification number: C12P21/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  C07K14/005 ,  C07K14/70596 ,  C07K16/1063 ,  C07K16/2803 ,  C12N9/16 ,  C12N9/48 ,  C12N2740/16122 ,  C12N2740/16134

Abstract: Methods of producing a carbohydrate HIV vaccine or immunogenic composition are provided. One method comprises expressing a glycoprotein with a modified glycosylation, which facilitates binding of the glycoprotein to the 2Gl 2 antibody. Another method comprises iteratively selecting cells with a high affinity for the 2Gl 2 antibody.

Abstract translation: 提供了生产碳水化合物HIV疫苗或免疫原性组合物的方法。 一种方法包括用修饰的糖基化来表达具有促进糖蛋白与2Gl抗体结合的糖蛋白。 另一种方法包括迭代地选择对2G1抗体具有高亲和力的细胞。